Llámenos: 787-782-8255

  • Bienvenidos a RF Mortgage

  • La hipoteca que necesita, el trato que merece.

  • Solicite Ahora



En RF MORTGAGE consideramos a cada cliente como un gran activo, no como un número más. Desde el año 1977 nuestro banco se ha destacado por hacer realidad los sueños de miles de clientes para adquirir su propio hogar.

Nuestros Productos

Tenemos el préstamo hipotecario ideal, si está listo para:

  1. Comprar su residencia principal
  2. Comprar una segunda vivienda
  3. Refinanciar su propiedad
  4. Comprar una propiedad para inversión o comercio
  5. Bajar el pago mensual de su hipoteca
  6. Reducir el término de su hipoteca
  7. Recibir de su nueva hipoteca un sobrante para lo que necesite


Inovio Suing Suppliers Over Covid-19 Vaccine Production

Inovio Suing Suppliers Over Covid-19 Vaccine ProductionInovio Pharmaceuticals (INO) has now initiated legal proceedings as an emergency action to compel the technology transfer required for the planned large-scale manufacture of its COVID-19 vaccine candidate.The company has an ambitious goal of producing one million doses of INO-4800 by the end of 2020, with its existing capacity and contract resources, for further clinical trials or emergency use.To fulfil this goal, INO has filed a complaint in Pennsylvania to compel VGXI, Inc. and GeneOne Life Science to facilitate the transfer of manufacturing methods, using VGXI’s technology, to the company’s new engaged contract manufacturers.“The Company believes that widespread availability of its potential COVID-19 vaccine, which can only be achieved through accelerated large-scale manufacture following clinical trials and regulatory approval, is essential to combat the ongoing global coronavirus pandemic” INO states.Under the companies’ Supply Agreement, VGXI produces and supplies the DNA plasmids for the INO’s research and early clinical trials for its product candidates.However VGXI allegedly informed Inovio that it did not have the capacity to manufacture the full order of DNA plasmids on the requested timeline, nor would it be able to manufacture plasmids for the commercial sale of INO-4800, if the vaccine were approved.It subsequently refused to transfer the technology to INO’s third party contract manufacturers.In January 2020, INO began preclinical studies of INO-4800, and in April it received approval from the U.S. FDA to begin a Phase 1 clinical trial of INO-4800. If the initial safety and immunogenicity data from the Phase 1 trial are acceptable, INO plans to advance the development of INO-4800 into later-stage efficacy trials in the second half of 2020.In a further dose of bad news, Inovio has not been selected by the Trump administration as one of the five companies picked to develop a COVID-19 vaccine as part of the government’s Warp Speed operation. The companies selected will receive additional government funding, assistance in clinical development and manufacturing to ensure the availability of two hundred million doses by YE2020.“Given INO’s notable omission from this list, we see these developments as a negative read-through to INO shares, though we would await a formal announcement, given INO’s need for external funding in further clinical development and manufacturing scale-up of their ph.I candidate, INO-4800” commented RBC Capital analyst Gregory Renza. Indeed, shares fell 13% on June 3, and are now falling 5% in Thursday’s pre-market trading.However the anlayst adds “While the news can be seen as initially disappointing… we think the announcement would not preclude INO from an ultimately successful development of a COVID-19 vaccine as they continue to leverage external funding support funding and maintain active engagement with gov’t agencies and other funders.”Renza reiterated his Hold rating on the stock with a $10 price target (20% downside potential) on June 3. INO stock has exploded over 270% year-to-date, and analysts have a cautiously optimistic Moderate Buy consensus on the stock’s outlook. That’s with a $17 average analyst price target for further upside potential of 34%. (See INO stock analysis on TipRanks).Related News: 5 Covid-19 Vaccines Picked For Trump’s Operation Warp Speed Inovio’s COVID-19 Vaccine Candidate Has the Edge Over Moderna’s, Says 5-Star Analyst Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Amazon Is Mulling To Buy $2 Billion Stake In Indian Telecom Bharti Airtel * Southwest Airlines Prices Two-Tranche $1.8 Billion Debt Offering * AstraZeneca Partners With Accent To Develop Novel Cancer Treatments * Nio Rising On Record-High Monthly Deliveries, Goldman Sachs Upgrade


Préstamos de Veteranos

Los préstamos de veteranos (VA) están garantizados por la Administración de Veteranos y ofrecen beneficios.  Entre para conocer más sobre este préstamo.


Haz Click

Préstamos FHA

El préstamo FHA es un préstamo asegurado con el fin de lograr que todo ciudadano tenga su residencia principal. Entre para conocer más sobre este 


Haz Click

Hipoteca Revertida

El programa de Hipoteca Revertida asegurada por la FHA puede ser utilizado para retirar parte del capital en su vivienda. 

Entre para conocer los beneficios de esta hipoteca.

Haz Click